Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
Status:
Completed
Trial end date:
2016-08-09
Target enrollment:
Participant gender:
Summary
Dose escalation study to determine the maximum tolerated dose of NEOD001 in approximately 30
subjects with AL amyloidosis. Expansion phase to evaluate safety, efficacy and
pharmacokinetics of NEOD001 in 25 additional subjects at the maximum tolerated dose.